We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oncimmune Holdings Plc | ONC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.50 | -2.13% | 23.00 | 16:35:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 24.00 | 24.00 | 24.00 | 23.00 | 23.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 12/10/2023 08:19 by brummy_git Encouraging new developments from IPR rich life science firm Oncimmune.All the details here. |
Posted at 31/5/2023 11:15 by eva_1989 I dont know what Trek from LSE smoking but i badly need same ;)He thought to pump before open so that he can sell to others... Hi R00st3R, I think todays interims answer your questions. All good at ONC. Well actually very good! Should be a cracking day today! Pity some of the revs got delayed but there is a line of sight and perhaps most importantly a change in sentiment. Wish I could buy more at this price! Usual caveats Trek |
Posted at 31/5/2023 09:33 by brummy_git H1'23 results out today from Oncimmune. All the details here. |
Posted at 22/5/2023 09:26 by brummy_git Very positive M&A and contract news from global immunodiagnostics group Oncimmune today.All the details here. |
Posted at 27/2/2023 07:13 by brummy_git Final results (y/e Aug'22) out today from global immunodiagnostics firm, OncimmuneAll the details here. |
Posted at 17/2/2023 08:56 by brummy_git Terrific news today from Oncimmune, who is partnering with with Siemens Healthineers to improve the assessment of indeterminate pulmonary nodules.All the details here. |
Posted at 20/12/2022 07:22 by brummy_git More encouraging contract wins for leading immunodiagnostics firm, Oncimmune.All the news and investor commentary here. www.linkedin.com/pos |
Posted at 14/12/2022 15:33 by brummy_git Leading immunodiagnostics firm Oncimmune successfully competes a £2.1m top up fund raise. All the details & commentary here.www.linkedin.com/pos |
Posted at 26/11/2022 07:18 by brummy_git There are 2 golden rules when investing in nascent healthcare stocks.Find out here what they are & potentially how to profit from these secular tailwinds. www.linkedin.com/pos |
Posted at 05/5/2021 07:56 by someuwin Zeus CapitalOncimmune ONC LN Biotechnology Reacquisition of IP and distribution rights for Chinese lung cancer test Oncimmune has reacquired IP and distribution rights for its lung cancer diagnostic (EarlyCDT®) that has been recalibrated for enhanced accuracy in Asian populations. Trials are due to complete in H1 2021, with regulatory filing to follow shortly afterwards. We would expect the company to be in advanced discussions with a new licensee/ distributor or acquirer of the geographically-speci Oncimmune has announced that it is reacquiring the IP and distribution rights for its EarlyCDT® lung cancer diagnostic in the Peoples Republic of China and Hong Kong, originally licensed to the Genostics Company Limited in January 2018. As part of the original deal Genostics made a £10m equity investment in Oncimmune. Genostics currently holds than less than a 5% share in Oncimmune. The cost of reacquisition has not been disclosed, and as such are likely to be relatively nonmaterial (i.e. < £1m). Since January 2018 Oncimmune and Genostics have been developing a lung cancer test with superior performance given the high prevalence rates of EGFR +ve non-small cell lung cancer in the China and Asia-Pacific regions. The test uses an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells that are specific to Asian populations. In May 2019 Oncimmune announced that the new test had entered a new multicentre case control study, in the People’s Republic of China assessing early detection of lung cancer, study approximately 1,000 early lung cancers at five leading academic health centres across China. The study is due to complete in H1 2021, with the data for the newly validated panel used to support approval of the test by Chinese regulators (the China National Medical Products Administration). Oncimmune has been actively pursuing a new licensing partner for EarlyCDT® in China, and we would be surprised if, given that regulatory filing is likely before midmid, the company was not in advanced discussions with either a new licensee, or even a potential acquirer. We would expect a new licensing agreement or divestment to be net value accretive. We note that a reduced dependency on China as part of overall corporate strategy may be beneficial given Oncimmune’s intention. Going forwards, to increase its focus on the US, both in terms of operations and capital markets. We maintain a positive outlook on the stock, although our valuation and current forecasts are currently under review pending an update by a new analyst." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
